Product image of Madopar Cr (Benserazide Hydrochloride, Levodopa) supplied by GNH India

Madopar Cr

Active Ingredient:
Benserazide Hydrochloride, Levodopa
Origin:
EU

Madopar Cr (Benserazide Hydrochloride, Levodopa)

Levodopa and benserazide, the active ingredients in Madopar CR, are a dopamine precursor and dopa decarboxylase inhibitor combination presented as a controlled‑release oral tablet for oral use. It treats the motor symptoms of Parkinson's disease in adult patients.

GNH India supplies Madopar CR as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to global markets. With a robust cold‑chain logistics network, GNH India ensures product integrity during transit.

Manufacturer / TM Owner

Roche Austria Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Madopar CR is used in the management of Parkinsonian disorders by replenishing central dopamine levels.
  • Parkinson's disease: improves motor function, reducing bradykinesia, rigidity and tremor.
  • Parkinsonian syndrome: alleviates symptoms in patients with idiopathic disease.
  • Levodopa‑responsive Parkinsonism: restores dopaminergic activity in patients who respond to levodopa therapy.

How It Works

  • Madopar CR combines levodopa, a dopamine precursor that crosses the blood‑brain barrier, with benserazide, a peripheral aromatic L‑amino‑acid decarboxylase inhibitor. Benserazide prevents the peripheral conversion of levodopa to dopamine, increasing the amount of levodopa that reaches the central nervous system where it is decarboxylated to dopamine, thereby augmenting deficient dopaminergic transmission in the basal ganglia. The controlled‑release formulation provides a more stable plasma levodopa concentration, reducing motor fluctuations.

Side Effects

Madopar CR may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Nausea
  • Vomiting
  • Dizziness
  • Orthostatic hypotension
  • Headache
  • Insomnia

Serious or Rare Side Effects

  • Dyskinesia
  • Hallucinations or psychosis
  • Severe hypotension
  • Cardiac arrhythmias
  • Neuroleptic malignant syndrome
  • Severe allergic reactions such as anaphylaxis

Precautions & Warnings

  • When prescribing Madopar CR, clinicians should consider several safety measures.
  • Dose titration: start with the lowest effective dose and increase gradually to minimize adverse effects.
  • Renal impairment: adjust dosing and monitor renal function in patients with reduced clearance.
  • Cardiovascular disease: monitor blood pressure and heart rate due to risk of orthostatic hypotension.
  • Psychiatric history: observe for hallucinations or confusion, especially in elderly patients.
  • Surgical procedures: withhold the drug before anesthesia to avoid interactions with anesthetic agents.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Madopar CR interacts with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors: risk of hypertensive crisis.
  • High‑dose pyridoxine (vitamin B6): reduces levodopa efficacy.
  • Antipsychotics (dopamine antagonists): antagonize therapeutic effect.
  • Sympathomimetics (e.g., epinephrine): may cause severe hypertension.
  • Iron or calcium supplements: impair levodopa absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: additive blood pressure lowering effect.
  • Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome.
  • Other antiparkinson drugs (COMT inhibitors, MAO‑B inhibitors): may require dose adjustment.
  • Anticholinergics: may increase anticholinergic burden.
  • Diuretics: monitor electrolytes and blood pressure.

Frequently Asked Questions

Madopar CR is a combination of levodopa and benserazide indicated for the treatment of Parkinson's disease. It helps control motor symptoms such as tremor, rigidity, and bradykinesia in adult patients.

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier; once inside the brain it is converted to dopamine, replenishing the deficient neurotransmitter in the basal ganglia and improving motor control.

The appropriate dose is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosing regimens are adjusted during follow‑up visits.

Safety in pregnancy and lactation has not been established; it should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity; GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with immediate‑release levodopa formulations, Madopar CR provides a controlled‑release profile that yields steadier plasma levels, reducing motor fluctuations. It differs from dopamine agonists, which act directly on dopamine receptors and have distinct side‑effect profiles.

Store tablets at ambient temperature below 25 °C in the original container, protected from moisture and direct light; do not refrigerate or expose to excessive heat.

The tablets are taken orally, usually with a small amount of food or water; they should be swallowed whole and not crushed or chewed to maintain the controlled‑release mechanism.

Serious adverse events include dyskinesia, severe hypotension, hallucinations, neuroleptic malignant syndrome, and rare allergic reactions. Patients should be monitored closely for these effects and seek medical attention if they occur.

Patients with known hypersensitivity to levodopa, benserazide, or any excipients, those taking non‑selective MAO inhibitors, and individuals with narrow‑angle glaucoma or severe cardiovascular disease should avoid the product unless directed otherwise by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Benserazide Hydrochloride, Levodopa

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT